MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2025 International Congress
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Lived Experiences in early clinical PD: Developing a Framework of a Novel Patient-reported Outcome (PRO) Fit-for-purpose for Disease Modification Therapeutic Trials

T. Mestre, J. Ding, N. Lapelle, G. Stebbins (Chicago, USA)

Meeting: 2025 International Congress

Keywords: Parkinson’s, Scales

Category: Parkinson’s Disease: Clinical Trials

Objective: To characterize the lived experience of individuals at a prodromal stage of PD or with a recent clinical diagnosis.

Background: There is no validated clinical outcome assessment (COA) for assessing functional impairment for people with Parkinson (PwP) in the earliest clinical stages. Development of such a COA would improve identification of PD patients who might benefit from early treatments, and the evaluation of the therapeutic effects for novel intervention in the setting of early disease modification trials.

Method: Mixed methods approach with focus groups followed by a survey about experience of symptoms, degree of bothersomeness, importance, and functional impact. We used purposive sampling for the focus group sessions (each session, n=10) considering the following criteria: Clinical diagnosis of PD AND on dopaminergic medication <1 year; clinical diagnosis of PD < 1yr ; prodromal condition (RBD or hyposmia), and care partners and/or knowledge informants. We conducted content analyses, with identification of symptoms and corresponding functional impacts, and descriptive statistics on the results of the post-focus group survey. A consensus was obtained using a modified Delphi panel technique.

Results: We identified functional impacts related to motor and non-motor symptoms from prodromal to clinical PD groups. The focus group sessions with caregivers highlighted large discrepancies between the changes noted by the individual and care partners, with very few additional changes reported by the latter. The post-focus group survey suggested that both motor and non-motor changes from normal were more commonly rated as bothersome but lacking significant functional impact, with exception of the “treated PD” group reporting greater impacts. The reported changes were grouped in the following domains after consensus: Tremor, Gross Motor/Mobility, Fine Motor/Dexterity, Sensory Changes, Cognition, Fatigue, Sleep, Behavioral/Mood Changes, Bulbar changes, Dysautonomia, Activities of Daily Living (for functional Impacts that span symptom domains).

Conclusion: The earliest lived experience of PwP includes a comprehensive set of motor and non-motor symptoms with functional impacts, even prior to a clinical diagnosis. The results support the development of a PRO on early functional impacts and informs a comprehensive item bank

To cite this abstract in AMA style:

T. Mestre, J. Ding, N. Lapelle, G. Stebbins. Lived Experiences in early clinical PD: Developing a Framework of a Novel Patient-reported Outcome (PRO) Fit-for-purpose for Disease Modification Therapeutic Trials [abstract]. Mov Disord. 2025; 40 (suppl 1). https://www.mdsabstracts.org/abstract/lived-experiences-in-early-clinical-pd-developing-a-framework-of-a-novel-patient-reported-outcome-pro-fit-for-purpose-for-disease-modification-therapeutic-trials/. Accessed October 5, 2025.
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2025 International Congress

MDS Abstracts - https://www.mdsabstracts.org/abstract/lived-experiences-in-early-clinical-pd-developing-a-framework-of-a-novel-patient-reported-outcome-pro-fit-for-purpose-for-disease-modification-therapeutic-trials/

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Life expectancy with and without Parkinson’s disease in the general population
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • AI-Powered Detection of Freezing of Gait Using Wearable Sensor Data in Patients with Parkinson’s Disease
  • Effect of Ketone Ester Supplementation on Motor and Non-Motor symptoms in Parkinson's Disease
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • Life expectancy with and without Parkinson’s disease in the general population
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Insulin dependent diabetes and hand tremor
  • Improvement in hand tremor following carpal tunnel release surgery
  • Impact of expiratory muscle strength training (EMST) on phonatory performance in Parkinson's patients
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley